The fight against multidrug-resistant (MDR) pathogens continues. This article discusses the gap between the need for new antibiotics and lean research and Thus, interest in antibiotics, particularly in drugs effective against MDR Gramnegative bacteria, is back. We appear to be at the start of a new wave of antibacterial drug R&D that will hopefully yield new therapeutic options in the future (10-15 years). Until then, the problem of MDR Gram-negative bacteria must continue to be addressed with a multifaceted set of solutions based on currently available tools.
Introduction
Over the last two decades the flow of new antibacterial drugs into the market has slowed, leaving a frequent gap between diagnosis of resistant pathogens and effective treatment options. Coupled with the rise of challenging infections, such as those caused by hospital-and community-acquired meticillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant (MDR) Gram-negative bacteria, this situation is of increasing concern to clinicians [1] [2] [3] [4] .
As has been observed in many fields, innovation in general proceeds in waves. This has been the historical case in the development of anti-infectives. The discovery of a new class of antimicrobials with novel mechanisms of action is usually followed by modified and improved molecules of the same class. For instance, in the 1970s to 1990s a wide variety of broad-spectrum antibiotics became available, such as cephalosporins, penicillin/-lactamase inhibitor combinations, carbapenems and fluoroquinolones. Empirical usage and coverage of a broad range of pathogens became an integral part of the therapeutic management, with little applied concern regarding the development of resistance. The industry's focus on blockbuster drugs (peak annual single product global sales of at least $1 billion) generated economic drivers completely at odds with the medical and social goals of anti-infectives [5, 6 ].
This business model, driven by hugely ambitious revenue and profit goals with expectations of short-term returns from the capital market, was not compatible with the short treatment of acute diseases. As many big companies focused on the search for products targeted at the far more lucrative chronic disease and life-style condition markets, they abandoned antibacterial research and development (R&D) in M a n u s c r i p t 4 the 1990s OR earlier. As a consequence, research sites were shut down, the accumulated knowledge dispersed and most R&D activities shifted to small companies.
With mostly broad-spectrum antibiotics available and in wide use, resistance problems developed. Indeed, numerous studies based on routine surveillance data indicate a strong relationship between use and resistance [7] . Still, many years passed before an ever-increasing mass of critical public health concerns regarding Numerous economic, societal, political, bacterial, scientific and medical factors are driving the development of antibiotics; this review cannot cover in any depth all of the important relevant aspects. Instead, it will present an outlook for the next 5-7 years for new systemic antibiotics that may be available for the treatment of resistant pathogens. Additionally, based on talks with industry leaders and other stakeholder groups, as well as reviewing available published sources, I will draft a future scenario for the next 10-15 years. If it is on target, this scenario will give rise to M a n u s c r i p t 5 some hope but will also require a change in usage patterns of antibiotics to bridge the gap in availability of novel drugs. (Fig. 1 ). Considering the bleak economic situation in most countries, rising healthcare costs and indicated political changes in the USA, price and proven benefit will be key factors in deciding the uptake of new antibiotics.
Current Gram-positive pipelines
A few companies pursue novel programmes with new targets that are now in early clinical development and focus mainly on Gram-positive bacteria. These drug development achievements will enrich our treatment options for infections caused by Gram-positive bacteria, especially MRSA, in the foreseeable future ( Table 1 ). The wave of Gram-positive focus in R&D continues to flow but appears to have hit its peak.
Analogues of existing molecules
For many years companies have been focusing on improving existing antibiotic groups with the goal of addressing MRSA. Typically, antibiotics with a Gram-positive focus are developed first for complicated skin and soft-tissue infection (cSSTI), which is the most suitable entrance indication for a new product (Fig. 2) . Primarily, -M a n u s c r i p t M a n u s c r i p t 7 Some years ago, glyco/lipopeptides arose as an active R&D field. Improvements have focused on bactericidal activity, long half-life and activity against vancomycinresistant strains. Encouraged by the recent commercial success of daptomycin (primarily in the USA), three other glycopeptides were further developed and submitted for approval. So far, only one of the glycopeptides appears to have been successful. In the USA, telavancin (Theravance Inc.) received a favourable opinion from the FDA advisory committee despite some safety concerns that will be managed by risk evaluation and mitigation strategy (REMS). As usual, the first indication for telavancin was cSSTI. In Europe, the application has been withdrawn but may be resubmitted with results including Gram-positive HAP data. Pfizer's dalbavancin was withdrawn due to repeated rejections by the FDA. Oritavancin, the third antibiotic in this group, was also rejected by the FDA owing to inconclusive efficacy in MRSA patients in one Phase 3 clinical trial that was carried out some years ago by the out-licenser. Oritavancin's European application is still pending.
Another old group that has been revived and improved is the tetracycline group with the derivate amadacycline (PTK 0796) (Paretek Pharmaceuticals, Inc). It has completed Phase 2 and oral/i.v. forms are being developed for cSSTI and CAP.
Novel molecules, new targets
All the abovementioned antibacterial compounds build on well known groups ( rRNA of the 50S bacterial ribosome subunit) have been known for a long time and are available as topical antibiotics (retapamulin) [9] . Systemically available pleuromutilins are now coming on the scene (Nabriva Therapeutics).
Current Gram-negative pipelines
Over the last few years the increase in MDR Gram-negative isolates has become apparent and even outpaces MRSA in certain European countries and elsewhere [10] . Compared with Gram-positives, the pipelines for infections caused by MDR Gram-negative pathogens are remarkably lean (Table 2 ). This situation has been extensively discussed in the infectious disease community [11] [12] [13] [14] [15] [16] . Here I provide information regarding drugs in pre-clinical and clinical testing that may be ca. CXA-101 (Calixa Therapeutics), a cephalosporin in pre-clinical development, is comparable with ceftazidime but is more stable to AmpC -lactamases [17] . This new cephalosporin overcomes some resistance determinants but does not solve the problem of multiresistance in Pseudomonas aeruginosa. This is also the case for the combination of Forest's investigational cephalosporin ceftaroline in combination with the abovementioned -lactamase inhibitor NXL 104. In addition to the improved activity of ceftaroline against staphylococci, this combination in pre-clinical development promises to be stable against most -lactamases in Gram-negative bacteria [18] . In contrast to the abovementioned cephalosporins with a broad spectrum, the pre-clinical monobactam BAL 30072 (Basilea Pharmaceutica Ltd.) focuses on non-fermenters, particularly Acinetobacter. The underexplored group of monobactams is inherently stable against class B -lactamases (metallo enzymes).
BAL 30072 is also stable against AmpC enzymes but lacks stability against extended-spectrum -lactamases) [19] . 
Novel molecules, new targets
Considering the widespread resistance problem and the propensity to intensify the effect of class-specific resistance mechanisms, most specialists would prefer a novel chemical class with no pre-existing potential cross-resistance [21] . Discovery 
Future scenario for antibacterial research and development
Over recent years the resistance situation in Gram-negative infections has received substantial attention [10, 24] . Reports regarding MDR P. aeruginosa, Acinetobacter spp. and enterobacteria such as Klebsiella spp. caused a revival in the use of very old and less characterised drugs such as colistin [25, 26] . Owing to the intensified need for new therapeutic options against MDR Gram-negative bacteria, the variables of the economic assessment in pharmaceutical companies have changed. So after many years of broad-spectrum antibiotics for empirical usage, the tide appears to have turned to the Gram-negative field and to more targeted therapy.
Although not yet apparent in the clinical pipelines shown in Table 2 A c c e p t e d M a n u s c r i p t 13 Whilst current medical practice makes empirical therapy a necessity [27, 28] , all signs and trends point towards targeted therapy options and more efficient usage of diagnostics [29] [30] [31] . Driven by financially challenged healthcare systems worldwide and enticed by successful examples of applied personalised medicine in the oncology field, the concurrent rise of reliable, easy to use, rapid molecular diagnostic capabilities promises to change treatment paradigms in everyday clinical practice.
Molecular diagnostics are the cornerstones of the emerging fields of pharmacogenomics and personalised medicine and are becoming increasingly entwined with the development of pharmaceutical drugs [32] . Serving as a model, companion development of rapid diagnostics and small-spectrum antibiotics provides an incentive for companies to study more seriously ill patients in late clinical development [33] . Usage of rapid diagnostics promises more efficient and faster enrolment of patients and also has the potential to provide robust evidence for safety and effectiveness in the exact group of patients in whom the drugs can make the most difference in decreasing mortality [34] . The coming years are expected to bring further advances in diagnostic technology and applications [36] . In the clinical setting, the diagnosis of bacterial infections carries numerous challenges that may be partly addressed by reliable rapid detection of pathogens [36] and guide selection of new targeted small-spectrum antibiotics. 
Conclusion
Markets create resistance and resistance creates markets [37] . The rise in MDR Gram-negative bacteria has become a worldwide threat and new classes of antimicrobials with novel mechanisms of action are urgently required. This increasing need has created a promising market opportunity for the pharmaceutical industry, with the prospect of a satisfying return of investment via targeted high prices deployed in small niche markets. My prediction based on monitoring activities in this field is that the next wave of antibacterial drug development has begun.
Changed market conditions are opening up a new era of interest in the development of Gram-negative drugs. As these drugs have a narrow spectrum, they will be accompanied by a new generation of rapid and reliable companion diagnostics.
However, owing to reduced resources and research infrastructure, as well as the typically protracted research and clinical development time, it will take many years to harvest the fruits of these efforts. The success of the next wave of antibiotics will require changes to the regulatory, clinical and reimbursement landscape and considerable challenges are ahead. Yet clear signs of renewed interest in the development of new antibiotics against the most problematic Gram-negative pathogens will take 10-15 years to be delivered into clinical practice. We must continue to address the challenge of multidrug resistance today in order to bridge the gap in antibacterial development. M a n u s c r i p t 
